Why Boston Scientific Corporation (BSX) stock moved
Boston Scientific Corporation (BSX) shares rose 1.1% to $42.04 as of October 8, 2026, a modest gain from the prior close of $41.58. BestStocks flagged the session as a major change for BSX. The move is tied to company news. Below, we break down what changed for BSX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Boston Scientific appoints Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer. New COO leadership signals operational restructuring to boost efficiency and support growth execution.
What it means for Boston Scientific Corporation investors
For Boston Scientific Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.1% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $62.71, implying +49.2% upside from $42.04. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 20 days out, the next report is the most likely near-term test of the move.
BSX price reaction
BSX last traded at $42.04, up $0.46 (+1.09%) from the previous close of $41.58. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $41.58 and $45.05, and it currently sits about 13% of the way up that band.
Bullish and bearish analyst opinions on Boston Scientific Corporation (BSX)
The consensus analyst price target on Boston Scientific Corporation (BSX) is $62.71, 49.2% above the recent $42.04. Over the past 90 days analysts logged 0 upgrades, 18 maintains, and 2 downgrades. Here is how the bullish and bearish cases on BSX line up.
The bullish case
- Wall Street's consensus price target of $62.71 implies +49.2% upside from $42.04.
- The Street's most bullish target is $100.00 (+137.9%).
- Positive 1.1% session move.
- Positive price momentum.
The bearish case
- 2 analyst downgrades in the past 90 days, most recently Citigroup to Neutral (2026-09-17).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 8, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BSX
In-depth BSX event analyses
Frequently asked questions about BSX
Why did Boston Scientific Corporation (BSX) stock move?
BSX rose 1.1% to $42.04. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did BSX stock rise?
BSX gained 1.09% ($0.46) versus the prior close of $41.58, last trading at $42.04 on 0.7× average volume.
When is Boston Scientific Corporation's next earnings date?
BSX's next earnings report is estimated for 2026-10-28 — about 20 days away.
What is the analyst price target for BSX?
The consensus analyst price target for BSX is $62.71, about 49.2% above the current $42.04. Over the past 90 days, analysts recorded 0 upgrades, 18 maintains, and 2 downgrades.
How BestStocks tracks BSX
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for BSX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 8, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.